Clinical Trials
Phase 3 Trial of CAM2029 vs Standard Treatments in GEP-NET Patients
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET.
